Closing Gaps in HAE Management: Understanding What Control Means for Your Patients with HAE

Hereditary angioedema (HAE) attacks are unpredictable and can be debilitating and potentially life-threatening. The burden of HAE disease and its treatment can negatively impact individuals’ quality of life (QoL). A group of internationally recognised HAE experts convened for a sponsored symposium, which took place on 14th June 2025 as part of the European Academy of Allergy & Clinical Immunology (EAACI) Congress held in Glasgow, UK, to discuss gaps in HAE management. They discussed how, despite evidence-based treatment guidelines that make recommendations for all HAE patients to carry on-demand treatment at all times, and that all attacks should be treated as early as possible, many patients do not carry medication or treat attacks early. The panel and audience heard HAE patient perspectives through video clips and survey responses and discussed how patient and physician perspectives differ in terms of disease control and management. The wide-ranging discussions between panel members highlighted some of the barriers that patients face when it comes to following treatment guidelines for on-demand treatment of HAE attacks and offered perspectives on what more needs to be done to overcome these hurdles to allow patients with HAE to be more in control of their disease.